322 related articles for article (PubMed ID: 12720530)
1. Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience.
Prummel MF; Bakker A; Wiersinga WM; Baldeschi L; Mourits MP; Kendall-Taylor P; Perros P; Neoh C; Dickinson AJ; Lazarus JH; Lane CM; Heufelder AE; Kahaly GJ; Pitz S; Orgiazzi J; Hullo A; Pinchera A; Marcocci C; Sartini MS; Rocchi R; Nardi M; Krassas GE; Halkias A
Eur J Endocrinol; 2003 May; 148(5):491-5. PubMed ID: 12720530
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
[TBL] [Abstract][Full Text] [Related]
3. Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.
Perros P; Žarković MP; Panagiotou GC; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi AM; Nardi M; Brix TH; Covelli D; Daumerie C; Eckstein AK; Fichter N; Ćirić S; Hegedüs L; Kahaly GJ; Konuk O; Lareida JJ; Okosieme OE; Leo M; Mathiopoulou L; Clarke L; Menconi F; Morris DS; Orgiazzi J; Pitz S; Salvi M; Muller I; Knežević M; Wiersinga WM; Currò N; Dayan CM; Marcocci C; Marinò M; Möller L; Pearce SH; Törüner F; Bernard M;
J Endocrinol Invest; 2020 Dec; 43(12):1717-1722. PubMed ID: 32474767
[TBL] [Abstract][Full Text] [Related]
4. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
[TBL] [Abstract][Full Text] [Related]
5. [Management of Graves' orbitopathy: evidence-based recommendations].
Ponto KA; Pitz S; Mann WJ; Weber MM; Pfeiffer N; Kahaly GJ
Dtsch Med Wochenschr; 2009 Dec; 134(49):2521-4. PubMed ID: 19941237
[TBL] [Abstract][Full Text] [Related]
6. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
[TBL] [Abstract][Full Text] [Related]
7. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
[TBL] [Abstract][Full Text] [Related]
8. Optimal management of Graves orbitopathy: a multidisciplinary approach.
Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy.
Yu Y; Hu YX; Lu MX; Ouyang ZL; Xu MT; Zhao LY; Wang M
Ophthalmol Ther; 2024 Apr; 13(4):1015-1024. PubMed ID: 38376797
[TBL] [Abstract][Full Text] [Related]
10. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
11. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
Edmunds MR; Boelaert K
Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
[TBL] [Abstract][Full Text] [Related]
12. Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III).
Schuh A; Ayvaz G; Baldeschi L; Baretić M; Bechtold D; Boschi A; Brix TH; Burlacu MC; Ciric J; Covelli D; Currò N; Donati S; Eckstein AK; Fichter N; Führer D; Horn M; Jabłońska-Pawlak A; Juri Mandić J; Kahaly GJ; Konuk O; Langbein A; Lanzolla G; Marcocci C; Marinò M; Miśkiewicz P; Beleslin BN; Pérez-Lázaro A; Pérez-López M; Ponto KA; Quinn A; Rudofsky G; Salvi M; Schittkowski MP; Tanda ML; Toruner F; Vaidya B; Hintschich CR
Br J Ophthalmol; 2024 Jan; 108(2):294-300. PubMed ID: 36627174
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Graves' ophthalmopathy in patients with Graves' disease presenting to a referral centre in north India.
Reddy SV; Jain A; Yadav SB; Sharma K; Bhatia E
Indian J Med Res; 2014 Jan; 139(1):99-104. PubMed ID: 24604044
[TBL] [Abstract][Full Text] [Related]
14. Type 2 diabetic patients with Graves' disease have more frequent and severe Graves' orbitopathy.
Le Moli R; Muscia V; Tumminia A; Frittitta L; Buscema M; Palermo F; Sciacca L; Squatrito S; Vigneri R
Nutr Metab Cardiovasc Dis; 2015 May; 25(5):452-7. PubMed ID: 25746910
[TBL] [Abstract][Full Text] [Related]
15. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
[TBL] [Abstract][Full Text] [Related]
17. Raising awareness of Graves' orbitopathy with early warning cards.
Mitchell AL; Hickey J; Vaidya B; Mason R; Ajjan R; Zammitt N; Perros P; Dayan C;
Clin Endocrinol (Oxf); 2017 Dec; 87(6):853-859. PubMed ID: 28755510
[TBL] [Abstract][Full Text] [Related]
18. Planning health care for patients with Graves' orbitopathy.
Sasim IV; Berendschot TT; van Isterdael C; Mourits MP
Graefes Arch Clin Exp Ophthalmol; 2008 Sep; 246(9):1315-21. PubMed ID: 18581132
[TBL] [Abstract][Full Text] [Related]
19. The phenotype of newly diagnosed Graves' disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study.
Bartalena L; Masiello E; Magri F; Veronesi G; Bianconi E; Zerbini F; Gaiti M; Spreafico E; Gallo D; Premoli P; Piantanida E; Tanda ML; Ferrario M; Vitti P; Chiovato L
J Endocrinol Invest; 2016 Dec; 39(12):1445-1451. PubMed ID: 27465670
[TBL] [Abstract][Full Text] [Related]
20. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
